Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
47.12 USD -3.50% Intraday chart for Legend Biotech Corporation -14.34% -21.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65 MT
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug MT
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday MT
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma MT
U.S. FDA approves expanded use of J&J's cancer cell therapy RE
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma CI
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy RE
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating MT
Legend Biotech Files Mixed-Securities Shelf Registration MT
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating MT
Legend Biotech, Johnson & Johnson Cancer Therapy Wins FDA Advisory Panel Nod MT
Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma CI
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy RE
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies RE
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday MT
Legend Biotech Corporation Announces Management Changes CI
Transcript : Legend Biotech Corporation, Q4 2023 Earnings Call, Mar 11, 2024
Legend Biotech Q4 Loss Narrows, Revenue Rises MT
Earnings Flash (LEGN) LEGEND BIOTECH CORPORATION Reports Q4 Revenue $79.5M MT
CPI, Tech Outlooks Cap Wall Street Pre-Bell; Asia, Europe Off MT
Futures Down Pre-Bell Ahead of Key Inflation Data; Asia Churns, Europe Falls MT
Chart Legend Biotech Corporation
More charts
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
48.83 USD
Average target price
86.31 USD
Spread / Average Target
+76.76%
Consensus
  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. News Legend Biotech Corporation
  5. Legend Biotech Says European Panel Recommends Label Expansion of Carvykti for Treatment of Multiple Myeloma